ePrints@IIScePrints@IISc Home | About | Browse | Latest Additions | Advanced Search | Contact | Help

Additive effect of zoledronic acid and alfacalcidol in the treatment of disuse osteoporosis in rats

Khajuria, Deepak Kumar and Disha, Choudhary and Razdan, Rema and Mahapatra, Roy D (2015) Additive effect of zoledronic acid and alfacalcidol in the treatment of disuse osteoporosis in rats. In: REVISTA BRASILEIRA DE REUMATOLOGIA, 55 (3). pp. 240-250.

[img] PDF
Rev_Bra_De_Reu_55-3_240_2015.pdf - Published Version
Restricted to Registered users only

Download (786Kb) | Request a copy
Official URL: http://dx.doi.org/10.1016/j.rbre.2014.08.006

Abstract

Objectives: Disuse by bed rest, limb immobilization or space flight causes rapid bone loss. We conducted the present study to investigate the therapeutic effects of zoledronic acid (ZOL), alone and in combination with alfacalcidol (ALP) in a rat model of disuse osteoporosis. Methods: In the present study, 3-month-old male Wistar rats had their right hind-limb immobilized (RHLI) for 10 weeks to induce osteopenia, then were divided into four groups: 1 - RHLI positive control; 2 - RHLI plus ZOL (50 mu g/kg, i.v. single dose); 3 - RHLI plus ALP (0.5 mu g/kg, oral gauge daily); 4- RHLI plus ALP (0.5 mu g/kg, oral gauge daily) plus ZOL (50 mu g/kg, i.v. single dose) for another 10 weeks. One group of non-immobilized rats was used as negative control. At the end of the treatment, the femurs were removed and tested for bone porosity, bone mechanical properties, and bone dry and ash weight. Results: Combination therapy with ZOL plus ALP was more effective in decreasing bone porosity than each drug administered as monotherapy in RHLI rats. With respect to improvement in the mechanical strength of the femoral mid-shaft, the combination treatment of ZOL plus ALP was more effective than each drug administered as a monotherapy. Moreover, combination therapy using ZOL plus ALF was more effective in improving dry bone and ash weight, than single-drug therapy using ZOL or ALP in RHLI rats. Conclusions: These data suggest that combination therapy with ZOL plus ALP represents a potentially useful therapeutic option for the treatment of disuse osteoporosis. (C) 2014 Elsevier Editora Ltda. All rights reserved.

Item Type: Journal Article
Related URLs:
Additional Information: Copy right for this article belongs to the ELSEVIER SCIENCE INC, 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
Keywords: Disuse osteoporosis; Rat model; Zoledronic acid; Alfacalcidol
Department/Centre: Division of Mechanical Sciences > Aerospace Engineering (Formerly, Aeronautical Engineering)
Others
Date Deposited: 05 Aug 2015 05:23
Last Modified: 05 Aug 2015 05:23
URI: http://eprints.iisc.ernet.in/id/eprint/52035

Actions (login required)

View Item View Item